Suven Life Sciences share news, announcements and annual reports
NSE: SUVENBSE: 530239Healthcare ServicesSmall Cap
Suven Life Sciences Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1995 on BSE, Oct 2003 on NSE
Last close ₹271.75up ₹12.90 (4.98%)BSE ₹271.75
Share price at the NSE close on 2 Nov 2026. Previous close ₹258.85.
2 Nov: open ₹260.10, high ₹275.50, low ₹256.30
52-week range of traded prices to 2 Nov 2026
₹124.11Low, 24 Mar 2026₹403.35High, 1 Sep 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹7,679 Cr806th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −100.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −63.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,18,38627.5% delivered
Suven Life Sciences share news and announcements
803 announcements, routine notices left out, newest first. Page 11 of 17.
Apr 2015
Mar 2015
Feb 2015
10 Feb · Board meeting
Board of Directors of the Company at its meeting held on February 10, 2015 has approved: Mr. P. Subba Rao, the GM (Finance & Costing) has been appointed as Chief Financial Officer (CFO) of the Company by the Board.10 Feb · Updates
3 Feb · Legal
Spurt in Volume : Substantial increase in trading volumes have been observed in Suven Life Sciences Limited.. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Suven Life Sciences Limited has vide its letter inter-alia stated, "There is no information pending with us as on date having a bearing on the price/volume behavior in the scrip."2 Feb · Board meeting
To consider, inter alia, and take on record the Un-audited Financial Results for the third quarter ended December 31, 2014.
Jan 2015
Dec 2014
Nov 2014
Oct 2014
Sep 2014
29 Sep · Meeting
Aug 2014
4 Aug · Board meeting
To consider, inter alia, and take on record the Un-audited Financial Results for the first quarter ended June 30, 2014. Further that Trading window for dealing in the securities of the company was closed from August 04, 2014 to August 13, 2014. Trading window will be opened from August 14, 2014.
Jul 2014
Jun 2014
May 2014
22 May · Meeting
Company has fixed Book Closure dates for the Register of members and Share Transfer from July 26, 2014 to July 29, 2014 (both days inclusive) for the purpose of dividend & Annual General Meeting of the Company scheduled to be held on August 12, 2014.22 May · Dividend
Board of Directors of the company at its meeting held on May 22, 2014 has recommended dividend Re.0.50 paisa per share(50% of face value Rs.1.00 each) with an additional Special Silver Jubilee year dividend of Rs.2.00 per share (200% of face value of Rs.1.00 each), aggregating to Rs.2.50 per share for the financial year 2013-14,